Tag Archive for: cgt

European Commission Grants Orphan Drug Designation for Vivet Therapeutics Gene Therapy Product for the Treatment of Cerebrotendinous Xanthomatosis (CTX)

/in

Pre-clinical data of VTX-806 in mice demonstrated normalization of metabolic parameters in blood and brain, and of upregulated compensatory enzymes EUR 4.9 million funding provided by French Government to develop VTX-806 as an effective treatment option to stabilize or reverse symptoms in CTX patients Paris, France, September 5, 2024 – Vivet Therapeutics (“Vivet”), a clinical […]

Read more

Vivet Therapeutics presents interim data on its Phase 1/2 GATEWAY trial for the Treatment of Wilson Disease at EASL Congress 2024

/in

VTX-801 increased ceruloplasmin ferroxidase activity and improved liver histology Encouraging safety and tolerability with no serious adverse events reported Paris, France, June 5, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, today announces the presentation of interim data on its international Phase […]

Read more

Study on Treatment of Wilson Disease in Japan Published in Japanese Journal of Gastroenterology and Hepatology

/in

Paris, France, May 30, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, today announces the publication of a peer reviewed paper titled ‘Treatment of Wilson Disease in Japan: An Insurance Claims Database Study’ in the Japanese Journal of Gastroenterology and Hepatology. Wilson […]

Read more

Highly experienced CDMO expert Michel Spagnol appointed Chairman of Astraveus

/in

Paris, France, 28 November, 2023 – Astraveus SAS (“Astraveus” or the “Company”), the creator of modular, microfluidic cell foundries that transform cell and gene therapy (CGT) manufacturing, today announces the appointment of Michel Spagnol as its new Chairman of the Board. Michel joins existing Board members Jérémie Laurent, CEO; Alain Huriez, Director; AdBio Partners; Christian […]

Read more

Astraveus awarded €10.4 million grant by the French government as part of France 2030 investment plan

/in

Significant endorsement by the French government programme that promotes excellence in research and manufacturing of novel biotherapies Advances the Company’s ambitions for its Lakhesys™ platform Total company funding now over €30 Million Paris, France, October 24, 2023 – Astraveus SAS (“Astraveus” or the “Company”), the creator of modular, microfluidic cell foundries that transform cell and […]

Read more